ABL DiagnosticsXPAR:ABLD +0.80%50 EBIT per Share is €0.03 as of Dec. 2025. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.77 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 527 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 92.98% on this metric.
ABL Diagnostics's EBIT per Share for the
six
months ended in Dec. 2025 was €0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.03.
During the past 3 years, the average EBIT per Share Growth Rate was 65.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for ABL Diagnostics's EBIT per Share or its related term are showing as below:
XPAR:ABLD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -83.4 Med: 2.85 Max: 65.1
Current: 65.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of ABL Diagnostics was 65.10% per year. The lowest was -83.40% per year. And the median was 2.85% per year.
XPAR:ABLD's 3-Year EBIT Growth Rate is ranked better than 92.98% of 527
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs XPAR:ABLD: 65.10
ABL Diagnostics (XPAR:ABLD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
ABL Diagnostics EBIT per Share Related Terms
ABL Diagnostics EBIT per Share Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a EBIT per Share of €0.03 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #37 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 7%.
Is ABL Diagnostics' EBIT per Share too high?
ABL Diagnostics' current EBIT per Share is €0.03. Based on the distribution chart, ABL Diagnostics ranks #37 out of 527 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #37 out of 527 companies for EBIT per Share. This places ABL Diagnostics in the top 7% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current EBIT per Share is €0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.77, compared to a current price of €2.52 — trading 67.6% below its estimated fair value. The current EBIT per Share is €0.03. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current EBIT per Share is €0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.52 is trading 67.6% below its estimated GF Value™ of €7.77.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
EBIT per Share: €0.03
GF Value™: €7.77 vs. price of €2.52 (67.6% below fair value)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score
Get the complete analysis for XPAR:ABLD
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
